Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

AbbVie : Leukaemia patients to get access to AbbVies Venclyxto via Cancer Drugs Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:11pm CET

The new treatment Venclyxto (venetoclax) is to be available to NHS patients in England with chronic lymphocytic leukaemia (CLL), the common form of adult leukaemia via the CDF while it accrues more cost-effectiveness data.

Venclyxto will be available to adults with difficult-to-treat types of chronic lymphocytic leukaemia those patients without 17p deletion or TP53 mutation who have failed both chemo-immunotherapy and a B-cell receptor (BCR) inhibitor.

Venclyxto has also been recommended for the treatment of adult CLL patients in the presence of 17p deletion or TP53 mutation who are either unsuitable for or have failed a BCR inhibitor.

The decision represents a U-turn from NICE, which had rejected Venclyxto in first draft guidance published in February.

But since then AbbVie has been in talks with NICE and in final guidance, the cost-effectiveness watchdog granted interim funding from the CDF.

This will allow NICE to gather further evidence to address uncertainties in the dossier of trial evidence submitted by AbbVie, while giving CLL patients a further treatment option when other drugs have failed.

One concern cited by NICE was how generalisable the results of trials were to clinical practice in England, as neither the M12-175 nor M14-032 trials included any UK centres.

NICE also questioned evidence showing that despite having several therapies, CLL appeared not to have a detrimental effect on health-related quality of life of patients in the Venclyxto trials.

The committee concluded that patients in the trials were not as sick as those for whom the drug would be an option in England, meaning the treatment benefits in the population were uncertain.

Although data showed overall survival was much higher with Venclyxto, NICEs independent appraisal committee said the relative survival benefit compared with best supportive care was likely to be biased in favour of Venclexto.

Venclexto is likely to cost between 50,000-60,000 per Quality Adjusted Life Year gained, above the 30,000 threshold usually used by NICE but it has extra leeway as end of life criteria apply.

Dr Peter Hillmen, professor of Experimental Haematology and honorary consultant haematologist at Leeds Teaching Hospitals NHS Trust, said: Todays recommendation is great news for patients with CLL who have failed existing treatments, and provides clinicians with an important new treatment option.

The studies that NICE has assessed to reach this positive decision represent a milestone in the management of relapsed/refractory CLL.

The early clinical data is compelling, showing survival benefits for this challenging group of patients, including some who achieved complete remission. I would anticipate that collection of further data through the CDF will confirm these extremely promising early findings.

Alice Butler, medical director at AbbVie, said: Working together with the NHS to collect more long-term data provides an important opportunity to understand the impact of venetoclax on the survival of patients with this difficult-to-treat type of CLL.

Patients in Wales are likely to get access to drug in the coming months following NICEs ruling, while the Scottish Medicines Consortium already recommended funding in August in a separate decision.

(c) Copyright: Arab News 2017 All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE
05:40aAN EAR TO THE PHARMA : 6 Stocks To Watch This Week
02/24ABBVIE : s Uterine Fibrosis Candidate Meets Goal in Study
02/23ABBVIE : Study Results from AbbVie Provide New Insights into Pentosyltransferase..
02/23ABBVIE : Researchers from AbbVie Detail New Studies and Findings in the Area of ..
02/23HERE ARE TODAY’S BIOTECH MOVER : Abbvie, Neurocrine and GW Pharmaceuticals
02/22ABBVIE : to Present at the Cowen and Company 38th Annual Health Care Conference
02/22ABBVIE : Nova Scotians living with Advanced Parkinson's Disease now have public ..
02/22VOYAGER THERAPEUTICS : VYGR) Rose To A 4-Month High On AbbVie Collaboration
02/22ABBVIE : rolls up another big win for elagolix as the prospective blockbuster sw..
02/21ABBVIE : Here’s What The AbbVie and Voyager Therapeutics Deal Really Means
More news
News from SeekingAlpha
02/23Tracking Larry Robbins' Glenview Capital Management Portfolio - Q4 2017 Updat.. 
02/23Call Options For Dividend Investors 
02/233 THINGS IN BIOTECH YOU SHOULD LEARN : February 22, 2018 
02/22IRA Portfolio 1 Year Buying-Selling Update And Now 5.8% Dividend Yield 
02/22My Top 10 Retirement Stocks 
Financials ($)
Sales 2018 32 143 M
EBIT 2018 14 063 M
Net income 2018 10 488 M
Debt 2018 22 102 M
Yield 2018 2,66%
P/E ratio 2018 17,64
P/E ratio 2019 15,27
EV / Sales 2018 6,54x
EV / Sales 2019 5,94x
Capitalization 188 B
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126 $
Spread / Average Target 6,7%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE21.56%188 235
MERCK KGAA-8.26%13 083